Ravi B. Patel

Sep 30, 2024 | jamanetwork.com | Sanjiv Shah |Bristol Myers Squibb |New jersey |Ravi B. Patel

Key PointsQuestion  What effect does the cardiac myosin inhibitor mavacamten have on cardiac biomarkers in patients with heart failure with preserved ejection fraction (HFpEF) and left ventricular ejection fraction (LVEF) of 60% or greater, and is mavacamten safe in these patients?

Apr 17, 2024 | jamanetwork.com | Ravi B. Patel |Frank E. Silvestry |Jan Komtebedde |Scott Solomon

Key PointsQuestion  What is the long-term effect of an atrial shunt device on cardiac structure and function in patients with heart failure and preserved or mildly reduced ejection fraction?

May 24, 2023 | jamanetwork.com | Ravi B. Patel

Cardiovascular Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure—Does the Story Begin and End With the Kidney? Empagliflozin and Diuretic Use in Patients with Heart Failure and Preserved Ejection Fraction Javed Butler, MD, MPH, MBA; Muhammad Shariq Usman, MD; Gerasimos Filippatos, MD, PhD; João Pedro Ferreira, MD, PhD; Michael Böhm, MD; Martina Brueckmann, MD; James L. Januzzi, MD; Sanjay Kaul, MD; Ileana L.